Aripiprazole-induced neuroleptic malignant syndrome

Prashant Tibrewal; Tarun Bastiampillai; Cutie Kannampuzha; Jennifer Hancox; Rohanjeet Dhillon

doi:10.1016/j.ajp.2017.02.002

Aripiprazole-induced neuroleptic malignant syndrome

Prashant Tibrewal, Tarun Bastiampillai, Cutie Kannampuzha, Jennifer Hancox, Rohanjeet Dhillon

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Abstract

Antipsychotics can be effective in augmenting mood-stabilisers for bipolar affective disorder (BPAD) but pose the risk of neuroleptic malignant syndrome (NMS). NMS is characterised by the classic tetrad of altered mental status, extrapyramidal symptoms (EPS), pyrexia and autonomic instability (Belvederi Murri et al., 2015) – typically developing in that order (Velamoor et al., 1994). The incidence of NMS in those treated with neuroleptics is low and has declined to 0.01–0.02% due to newer atypical antipsychotic medication, improved prescribing practice, and earlier detection and management of NMS (Berman, 2011). We describe a case of aripiprazole-induced NMS in a patient with a prior history of NMS.

Original language	English
Pages (from-to)	5-6
Number of pages	2
Journal	Asian Journal of Psychiatry
Volume	27
Early online date	9 Feb 2017
DOIs	https://doi.org/10.1016/j.ajp.2017.02.002
Publication status	Published - Jun 2017
Externally published	Yes

Keywords

Aripiprazole
Neuroleptic Malignant Syndrome
Antipsychotics

Access to Document

10.1016/j.ajp.2017.02.002Licence: In Copyright

Fingerprint Dive into the research topics of 'Aripiprazole-induced neuroleptic malignant syndrome'. Together they form a unique fingerprint.

Cite this

@article{13744e6ba6dd4522b51bb1f69601ef30,

title = "Aripiprazole-induced neuroleptic malignant syndrome",

abstract = "Antipsychotics can be effective in augmenting mood-stabilisers for bipolar affective disorder (BPAD) but pose the risk of neuroleptic malignant syndrome (NMS). NMS is characterised by the classic tetrad of altered mental status, extrapyramidal symptoms (EPS), pyrexia and autonomic instability (Belvederi Murri et al., 2015) – typically developing in that order (Velamoor et al., 1994). The incidence of NMS in those treated with neuroleptics is low and has declined to 0.01–0.02% due to newer atypical antipsychotic medication, improved prescribing practice, and earlier detection and management of NMS (Berman, 2011). We describe a case of aripiprazole-induced NMS in a patient with a prior history of NMS.",

keywords = "Aripiprazole, Neuroleptic Malignant Syndrome, Antipsychotics",

author = "Prashant Tibrewal and Tarun Bastiampillai and Cutie Kannampuzha and Jennifer Hancox and Rohanjeet Dhillon",

year = "2017",

month = jun,

doi = "10.1016/j.ajp.2017.02.002",

language = "English",

volume = "27",

pages = "5--6",

journal = "Asian Journal of Psychiatry",

issn = "1876-2018",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Aripiprazole-induced neuroleptic malignant syndrome

AU - Tibrewal, Prashant

AU - Bastiampillai, Tarun

AU - Kannampuzha, Cutie

AU - Hancox, Jennifer

AU - Dhillon, Rohanjeet

PY - 2017/6

Y1 - 2017/6

N2 - Antipsychotics can be effective in augmenting mood-stabilisers for bipolar affective disorder (BPAD) but pose the risk of neuroleptic malignant syndrome (NMS). NMS is characterised by the classic tetrad of altered mental status, extrapyramidal symptoms (EPS), pyrexia and autonomic instability (Belvederi Murri et al., 2015) – typically developing in that order (Velamoor et al., 1994). The incidence of NMS in those treated with neuroleptics is low and has declined to 0.01–0.02% due to newer atypical antipsychotic medication, improved prescribing practice, and earlier detection and management of NMS (Berman, 2011). We describe a case of aripiprazole-induced NMS in a patient with a prior history of NMS.

AB - Antipsychotics can be effective in augmenting mood-stabilisers for bipolar affective disorder (BPAD) but pose the risk of neuroleptic malignant syndrome (NMS). NMS is characterised by the classic tetrad of altered mental status, extrapyramidal symptoms (EPS), pyrexia and autonomic instability (Belvederi Murri et al., 2015) – typically developing in that order (Velamoor et al., 1994). The incidence of NMS in those treated with neuroleptics is low and has declined to 0.01–0.02% due to newer atypical antipsychotic medication, improved prescribing practice, and earlier detection and management of NMS (Berman, 2011). We describe a case of aripiprazole-induced NMS in a patient with a prior history of NMS.

KW - Aripiprazole

KW - Neuroleptic Malignant Syndrome

KW - Antipsychotics

UR - http://www.scopus.com/inward/record.url?scp=85014438389&partnerID=8YFLogxK

U2 - 10.1016/j.ajp.2017.02.002

DO - 10.1016/j.ajp.2017.02.002

M3 - Letter

VL - 27

SP - 5

EP - 6

JO - Asian Journal of Psychiatry

JF - Asian Journal of Psychiatry

SN - 1876-2018

ER -

Aripiprazole-induced neuroleptic malignant syndrome

Abstract

Keywords

Access to Document

Other files and links

Cite this